Quick answers
- What is Eletriptan hydrobromide used for?
- The FDA-approved label (Relpax, Viatris Specialty LLC, January 15, 2024) says: “RELPAX is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks. • RELPAX is not intended for the prevention of migraine attacks. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Eletriptan hydrobromide have a boxed warning?
- No. None of the 13 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Eletriptan hydrobromide?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Eletriptan hydrobromide been recalled?
- FDA enforcement reports list 1 recall of products of this medicine; the newest started March 15, 2021 (Class II). A recall usually concerns specific lots, not every product.
- Who makes Eletriptan hydrobromide?
- 11 companies list prescription products of Eletriptan hydrobromide in the FDA NDC Directory, including Teva Pharmaceuticals USA, Inc., Aurobindo Pharma Limited and Bryant Ranch Prepack.
What Eletriptan hydrobromide is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
RELPAX is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks. • RELPAX is not intended for the prevention of migraine attacks. …
— FDA label: Relpax, Viatris Specialty LLC, effective January 15, 2024. Read the full label on DailyMed →
The FDA has 13 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 13 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Tablet, film coated · Tablet |
|---|---|
| Route | Oral |
| Prescription products | 21 in the FDA NDC Directory |
| Brand names | Relpax |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| eletriptan hydrobromide 20 mg tablet | Brand: Relpax | $77.37 per tablet |
| eletriptan hydrobromide 20 mg tablet, film coated | Generic | $1.59 per tablet |
| eletriptan hydrobromide 40 mg tablet | Brand: Relpax | $77.08 per tablet |
| eletriptan hydrobromide 40 mg tablet, film coated | Generic | $1.76 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Teva Pharmaceuticals USA, Inc.2 products
- Aurobindo Pharma Limited2 products
- Bryant Ranch Prepack2 products
- Direct_Rx2 products
- Viatris Specialty LLC2 products
- Camber Pharmaceuticals, Inc.2 products
- Zydus Lifesciences Limited2 products
- Apnar Pharma LP2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Mylan Pharmaceuticals Inc.2 products
- Advanced Rx of Tennessee, LLC1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA021016 RELPAX | Upjohn | December 26, 2002 | 13, latest March 24, 2020 2020: Labeling · 2015: Manufacturing (CMC) · 2013: Manufacturing (CMC) |
Generic approvals (7)
- ANDA206409Zydus Pharms · June 16, 2017
- ANDA202040Teva Pharms USA · June 27, 2017
- ANDA205152Mylan · August 11, 2017
- ANDA205186Chartwell Rx · August 29, 2017
- ANDA210708Aurobindo Pharma · January 15, 2019
- ANDA215467Regcon Holdings · July 13, 2022
- ANDA219143Annora Pharma · July 7, 2025
Shortage status
The FDA drug shortage list does not show these products.
Recalls
From FDA enforcement reports, matched by the product’s NDC code. A recall usually covers specific lots only: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
March 15, 2021 · Class II · Terminated · D-0438-2021
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
Eletriptan Hydrobromide Tablets 20 mg* 6(1x6) Unit-dose Tablets Rx only NDC 59651-104-69 Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Highstown Road East Windsor, NJ 08520 — Cardinal Health Inc.
What do the recall classes mean?
Class I: The most serious type: there is a reasonable chance that using the product will cause serious health problems or death.
Class II: Using the product may cause temporary or medically reversible health problems, or the chance of serious problems is remote.
Class III: Using the product is not likely to cause health problems (for example a labeling or packaging issue).
Official identifiers
| RxCUI (RxNorm) | 359493, 359494, 404443, 404444 |
|---|---|
| SPL set ID of the quoted label | 2a501dbd-3ea8-47e4-9fcb-07035b8c8c9e |
| FDA labels (SPL) | 13 |
| FDA applications | NDA021016, 7 ANDA |
| Active ingredients (FDA) | ELETRIPTAN |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Relpax, Viatris Specialty LLC, effective January 15, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →